These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

518 related items for PubMed ID: 20371718

  • 21. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
    Bian P, Hu W, Liu C, Li L.
    Arch Biochem Biophys; 2020 Aug 15; 689():108461. PubMed ID: 32531316
    [Abstract] [Full Text] [Related]

  • 22. Brassinin induces apoptosis in PC-3 human prostate cancer cells through the suppression of PI3K/Akt/mTOR/S6K1 signaling cascades.
    Kim SM, Park JH, Kim KD, Nam D, Shim BS, Kim SH, Ahn KS, Choi SH, Ahn KS.
    Phytother Res; 2014 Mar 15; 28(3):423-31. PubMed ID: 23686889
    [Abstract] [Full Text] [Related]

  • 23. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ.
    Cancer Res; 2006 Jul 01; 66(13):6589-97. PubMed ID: 16818631
    [Abstract] [Full Text] [Related]

  • 24. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y, Di W, Yang Q, Lu Z, Cai W, Wu J.
    Clin Lab; 2015 Jul 01; 61(8):1043-51. PubMed ID: 26427150
    [Abstract] [Full Text] [Related]

  • 25. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Locatelli SL, Giacomini A, Guidetti A, Cleris L, Mortarini R, Anichini A, Gianni AM, Carlo-Stella C.
    Leukemia; 2013 Aug 01; 27(8):1677-87. PubMed ID: 23360848
    [Abstract] [Full Text] [Related]

  • 26. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
    Momota H, Nerio E, Holland EC.
    Cancer Res; 2005 Aug 15; 65(16):7429-35. PubMed ID: 16103096
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
    De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N.
    Neoplasia; 2014 Jan 15; 16(1):43-72. PubMed ID: 24563619
    [Abstract] [Full Text] [Related]

  • 29. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
    Petrich AM, Leshchenko V, Kuo PY, Xia B, Thirukonda VK, Ulahannan N, Gordon S, Fazzari MJ, Ye BH, Sparano JA, Parekh S.
    Clin Cancer Res; 2012 May 01; 18(9):2534-44. PubMed ID: 22338016
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro.
    Chen MB, Wu XY, Tao GQ, Liu CY, Chen J, Wang LQ, Lu PH.
    Int J Cancer; 2012 Dec 01; 131(11):2487-98. PubMed ID: 22438101
    [Abstract] [Full Text] [Related]

  • 32. Defining the role of TORC1/2 in multiple myeloma.
    Maiso P, Liu Y, Morgan B, Azab AK, Ren P, Martin MB, Zhang Y, Liu Y, Sacco A, Ngo H, Azab F, Quang P, Rodig SJ, Lin CP, Roccaro AM, Rommel C, Ghobrial IM.
    Blood; 2011 Dec 22; 118(26):6860-70. PubMed ID: 22045983
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.
    Clin Cancer Res; 2004 Dec 01; 10(23):8059-67. PubMed ID: 15585641
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization.
    Han K, Xu X, Chen G, Zeng Y, Zhu J, Du X, Zhang Z, Cao B, Liu Z, Mao X.
    J Hematol Oncol; 2014 Jan 15; 7():9. PubMed ID: 24428908
    [Abstract] [Full Text] [Related]

  • 40. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.
    Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK.
    Mol Cancer Ther; 2003 Nov 15; 2(11):1093-103. PubMed ID: 14617782
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.